Last $13.97 USD
Change Today -0.04 / -0.29%
Volume 663.6K
THRX On Other Exchanges
Symbol
Exchange
Munich
NASDAQ GS
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Michael W. Aguiar

Chief Executive Officer, President and Director, Theravance Inc.
AgeTotal Calculated CompensationThis person is connected to 4 board members in 1 different organizations across 1 different industries.

See Board Relationships
48$856,188
As of Fiscal Year 2013

Background*

Mr. Michael W. Aguiar, also known as Mike, has been the Chief Executive Officer and President of Theravance Inc. since August 15, 2014. Mr. Aguiar served as the Chief Financial Officer of Theravance Inc since March 7, 2005 and served as its Principal Accounting Officer and Treasurer. He has also been Senior Vice President of Finance at Theravance Inc. since March 7, 2005 and served as Secretary. He served as Vice President of Finance at Gilead Sciences. In his two years ...

Read Full Background

Corporate Headquarters*

901 Gateway Boulevard
South San Francisco, California 94080

United States

Phone: 650-238-9600
Fax: --

Board Members Memberships*

2014-Present
Chief Executive Officer, President and Director

Education*

MBA
University of Michigan
BS
University of California, Irvine

Other Affiliations*

Annual Compensation*

Salary$457,007
Bonus$58,432
Total Annual Compensation$515,439

Stock Options*

Restricted Stock Awards$111,100
All Other Compensation$500
Exercised Options170,879
Exercised Options Value$2,706,723
Exercisable Options120,250
Exercisable Options Value$458,800
Total Value of Options$3,165,523
Total Number of Options291,129

Total Compensation*

Total Annual Cash Compensation$745,088
Total Short Term Compensation$515,439
Other Long Term Compensation$111,600
Total Calculated Compensation$856,188
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THRX:US $13.97 USD -0.04

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
$831.2K
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
$100.0K
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science & Strategy Committee
Progenics Pharmaceuticals, Inc.
$535.6K
Peter S. Greenleaf Chief Executive Officer, Director, Member of Commercialization Committee and Member of Science & Technology Committee
Sucampo Pharmaceuticals, Inc.
--
Richard Martin Steeves Ph.D.Group Chief Executive Officer, Member of Senior Executive Board and Executive Director
Synergy Health plc
823.0K GBP
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERAVANCE INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.